Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial
Primary result · Change in number of ventricular arrhythmiasResult — go to the resultCoefficient for the between-group difference - 1.07 95% CI - 1.29 to - 0.86Authors' conclusion
In patients with type 2 diabetes treated with ICD/CRT-D, empagliflozin reduces the number of ventricular arrhythmias compared with placebo.
Study context
- Population
- Patients with T2D treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator (ICD/CRT-D)
- Participants
- 150 patients
- Comparison
- Once-daily empagliflozin vs placebo for 24 weeks
- Primary endpoint
- Change in the number of ventricular arrhythmias from the 24 weeks before to the 24 weeks during treatment
- Follow-up
- 24 weeks
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
Change in number of ventricular arrhythmias · 24 weeks during vs 24 weeks before treatment
Coefficient for the between-group difference
- 1.07
95% CI - 1.29 to - 0.86
P < 0.001
As reported in the abstract
- Empagliflozin: number of ventricular arrhythmias decreased by
- 1.69
- Placebo: number of ventricular arrhythmias increased by
- 1.79
Secondary outcomes
| Outcome | Empagliflozin | Placebo | P value |
|---|---|---|---|
| Change in number of appropriate device discharges · during vs before treatmentNo significant difference | 0.06 | 0.27 | P = 0.204 |
Other values
- Empagliflozin associated with increased blood ketones and hematocrit and decreased blood brain natriuretic peptide and body weight
Original publication
Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial. Cardiovasc Diabetol. Published 28 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →